Cancer vaccines: Building a bridge over troubled waters.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35835100.
- Also identified by DOI 10.1016/j.cell.2022.06.035 and PMC identifier 9555301.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review the essential immunologic concepts underpinning natural immunity and highlight the multiple unique challenges faced by vaccines targeting cancer. Recent technological advances in mass spectrometry, neoantigen prediction, genetically and pharmacologically engineered mouse models, and single-cell omics have revealed new biology, which can help to bridge this divide. We particularly focus on translationally relevant aspects, such as antigen selection and delivery and the monitoring of human post-vaccination responses, and encourage more aggressive exploration of novel approaches.
Medical subject headings
- Cancer Vaccines
- Neoplasms
- Vaccines